EMERYVILLE, Calif., Sept. 20, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo, will present the results of a study on the effects of two botanically-derived, tissue selective estrogen receptor modulators for the treatment of obesity at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington DC on Friday, September 23, 2011.
On average, women transitioning through menopause experience a 10-15 pound weight gain with a redistribution of fat to the abdomen. Menopausal changes of body weight and increased central distribution of body fat have been identified as independent predictors of cardiovascular disease and type 2 diabetes. Dr. Tagliaferri will present studies that identify a new class of botanically-derived, tissue selective estrogen receptor modulators in adipose tissue which cause weight loss in mice without the unwanted proliferative effects in breast and uterine tissue that are associated with cancer.
In this study, ovariectomized female mice, mimicking menopause, were placed on a high fat diet for one month prior to initiation of treatment. While the untreated mice continued to gain weight, the mice administered with estrogens or the botanically-derived tissue selective estrogen receptor modulators lost weight. While estrogens had positive effects on the body fat mass, they significantly increased the size of the mammary gland and uterus. In contrast, the botanically-derived tissue selective estrogen receptor modulators did not adversely affect either the breast or uterine tissue. These findings suggest that the development of botanically-derived, tissue selective estrogen receptor modulators result in safer alternatives for the treatment of menopausal weight gain and the prevention of cardiovascular disease, type 2 diabetes and metabolic syndrome.
"Our scientific discoveries continue to show that Bionovo has a robust pipeline of drugs for the treatment of women's health that are safer than currently available therapies and in large demand by physicians and patients alike. There are 40 million women transitioning through menopause and a selective therapy that prevents weight gain through menopause would have enormous commercial potential," said Isaac Cohen, Chairman and CEO of Bionovo. "Metabolic syndrome can affect as many as 30% of postmenopausal women and being overweight and obese leads to an increase in morbidity and mortality. We believe that the tissue selective estrogen receptor modulators represent an exciting new class of drugs that have the potential to protect postmenopausal women from the many health risks associated with weight gain without increasing the risks of breast and endometrial cancer like the current estrogens used in hormone therapy."
About Bionovo, Inc.
Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
SOURCE Bionovo, Inc.